Maxim Group Analysts Give ContraVir Pharmaceuticals (CTRV) a $4.00 Price Target

Maxim Group set a $4.00 price objective on ContraVir Pharmaceuticals (NASDAQ:CTRV) in a research note released on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Separately, ValuEngine raised ContraVir Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, February 2nd.

Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at $0.25 on Monday. The company has a market capitalization of $20.54, a price-to-earnings ratio of -0.51 and a beta of 1.79. ContraVir Pharmaceuticals has a 12-month low of $0.23 and a 12-month high of $1.96.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Vanguard Group Inc. boosted its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,414,475 shares of the biopharmaceutical company’s stock after buying an additional 366,192 shares during the quarter. Vanguard Group Inc. owned approximately 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent SEC filing. 6.71% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Maxim Group Analysts Give ContraVir Pharmaceuticals (CTRV) a $4.00 Price Target” was first published by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://baseballnewssource.com/markets/maxim-group-analysts-give-contravir-pharmaceuticals-ctrv-a-4-00-price-target/1886548.html.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.